4 ms·
The half + full dose regime appears to have greater efficacy but wasn't approved because of insufficient data. I hope more data comes in and permits this. Also:
by cranekam 6y ago
The half + full dose regime appears to have greater efficacy but wasn't approved because of insufficient data. I hope more data comes in and permits this. Also:
"However, unpublished data suggests that leaving a longer gap between the first and second doses increases the overall effectiveness of the jab."
That may well help too. But at the end of the day, the world needs a lot of vaccine. It's better to have Pfizer/Moderna and the Oxford vaccine at our disposal, particularly when the latter is also much cheaper and easier to store (this will be crucial in developing countries and/or rural populations). What matters is having fewer people get sick or die, not ensuring everyone is given the vaccine with the greatest efficacy.
- grey-area 6y agoThe world would have 2x the vaccine available if they can fast track approval of the lower first dose. Hopefully given the prevalence in the UK they can now quickly do that work.
- snovv_crash 6y agoThat assumes the bottleneck is in the actual vaccine constituents, and not in manufacturing or sourcing the billions of delivery mechanisms.
- ummonk 6y agoFreezers, vials, and syringes are all easily mass produceable and already available in large quantities.
- snovv_crash 6y agoYes, but this isn't software. Out in the physical world supply chains take time to ramp up.
- hef19898 6y agoAnd they are ramping pretty fast right now. We are not talking about books shipped by Amazon here. I for my part am really satisfied with vaccine distribution right now, quite the opposite to mask distribution and sourcing.
- mft_ 6y ago4/3x?
- grey-area 6y ago2x the initial rate, assuming we are constrained by supply right now but not so later on. In a few months supplies in developed countries will probably be sufficient for other things like logistics to be a bigger constraint.